Is continuous ambulatory peritoneal dialysis responsible for an increase in plasma norepinephrine?
It is concluded that CAPD in patients with end-stage renal disease is responsible for a progressive increase of plasma norepinephrine.
The impact of DFT testing on 5-year survival in ICD patients, if it exists, is small. Survival appears higher with DFT testing as long as annual risk of lethal arrhythmia or the risk of a narrow safety margin is at least 5%, although the incremental benefit is marginal and 95% confidence intervals cross zero. A prospective randomized study of DFT testing in modern devices is warranted.